Oxbow Advisors LLC Takes $230,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Oxbow Advisors LLC purchased a new position in AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,958 shares of the company’s stock, valued at approximately $230,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in shares of AstraZeneca in the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca in the 1st quarter valued at about $29,000. Finally, RFP Financial Group LLC boosted its holdings in AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN opened at $64.49 on Friday. The company has a market cap of $199.96 billion, a PE ratio of 31.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The stock has a 50-day moving average of $77.07 and a 200-day moving average of $78.56. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.

Analyst Ratings Changes

Several research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.